Synthesis and cytotoxic properties of novel (E)-3-benzylidene-7-methoxychroman-4-one derivatives by Saeedeh Noushini et al.
Noushini et al. DARU Journal of Pharmaceutical Sciences 2013, 21:31
http://www.darujps.com/content/21/1/31RESEARCH ARTICLE Open AccessSynthesis and cytotoxic properties of novel
(E)-3-benzylidene-7-methoxychroman-4-one
derivatives
Saeedeh Noushini1, Eskandar Alipour1, Saeed Emami2, Maliheh Safavi3, Sussan Kabudanian Ardestani3,
Ahmad Reza Gohari4, Abbas Shafiee5 and Alireza Foroumadi4,5*Abstract
Background and the purpose of the study: There has been increscent interest in the field of cancer
chemotherapy by discovery and development of novel agents with high efficacy, low toxicity, and minimum side
effects. In order to find new anticancer agents, we replaced the pyrazolone part of well-known cytotoxic agent
SJ-172550 with 7-methoxychroman-4-one. Thus, a novel series of 3-benzylidene-4-chromanones were synthesized
and tested in vitro against human cancer cell lines.
Methods: The title compounds were prepared by condensation of 7-methoxychroman-4-one with suitable
aldehydes in appropriate alcohol in the presence of gaseous HCl. The antiproliferative activity of target compounds
were evaluated against MDA-MB-231 (breast cancer), KB (nasopharyngeal epidermoid carcinoma) and SK-N-MC
(human neuroblastoma) cell lines using MTT assay.
Results: Although the direct analog of SJ-172550 (compound 5d) did not show any cytotoxic activity against
tested cell lines, but 2-(2-chloro-6-methoxyphenoxy)acetic acid methyl ester analog 5c showed some activity
against MDA-MB-231 and SK-N-MC cells. Further modification of compound 5c resulted in the 3-chloro-4,5-
dimethoxybenzylidene derivative 5b which demonstrated better cytotoxic profile against all tested cell lines
(IC50 values = 7.56–25.04 μg/ml).
Conclusion: The results demonstrated that the cytotoxic activity of compound 5b against MDA-MB-231 and
SK-N-MC cells is more than etoposide. Therefore, compound 5b prototype could be considered as novel cytotoxic
agent for further developing new anticancer chemotherapeutics.
Keywords: Synthesis, Chalcones, Cytotoxic activity, Cancer, Chroman-4-oneIntroduction
Cancer has been known as one of the most impressive
clinical problems in both developing and developed
countries. In spite of improved diagnostic techniques
and advances in prevention and chemotherapeutic man-
agement of cancer, the disease still afflicts millions of
peoples in the world [1]. Cancer cells are defined by un-
controlled replications associated with self-sufficiency in* Correspondence: aforoumadi@yahoo.com
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reproduction in any medium, provided the orgrowth signals, hyposensitivity to anti-growth signals,
ongoing angiogenesis, metastasis, and evasion of apop-
tosis [2]. Anti-cancer agents cannot recognize cancer
cells from normal cells, as a matter of fact, these agents
usually act on metabolically active or rapidly proliferat-
ing cells [3]. Thus, there has been increscent interest in
the field of cancer chemotherapy by discovery and devel-
opment of novel agents with high efficacy, low toxicity,
and minimum side effects.
During recent years, several researchers developed dif-
ferent chalcone-like compounds with anticancer activity
through the introduction of heterocyclic scaffolds [4,5].
The chemical structure of chalcone is characterized by
two aromatic rings connected by a three carbon, α,β-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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one) [6-8]. The highly significant advantage of chalcone
derivatives as cytotoxic agents is the low propensity to
interact with DNA; which omits the risk of mutagenesity
as the common side effect of current chemotherapeutic
agents [9].
Previously, Perjési et al. have reported cytotoxicity of 3-
benzylidene-4-chromanones as rigid analogs of chalcones
(Figure 1) [10]. Recently, high-throughput screening of
drug libraries results in the identification of SJ-172550 that
exhibited p53-dependent cytotoxic activity against cancer
cell lines [11]. Structurally, SJ-172550 is characterized by
having α,β-unsaturated carbonyl system attached to the 2-
(2-chloro-6-ethoxyphenoxy)acetic acid methyl ester. Ac-
cordingly, in continuation of our research program to find
novel anti-cancer agents [12-16] and considering the
diverse biological activities of rigid chalcones [17], we have
synthesized a series of 3-benzylidene-4-chromanones
bearing 2-(2-chloro-6-alkoxyphenoxy) acetic acid esters.
The related analogs of 3-benzylidene-4-chromanones were




All chemical reagents and solvents were provided from
Merck AG (Darmstadt, Germany). The general proce-
dures for the synthesis of 3-benzylidene-4-chromanones
5a–k, and aldehyde intermediates (compounds 7–9 and
11) are illustrated in Schemes 1 and 2, respectively. 7-
Methoxychroman-4-one (4) was prepared as literature
method [18,19]. Melting points of compounds were
determined using Kofler hot stage apparatus and areFigure 1 Structure of 3-benzylidene-4-chromanones as rigid analogs
as a lead compound that showed cytotoxic effects against tumour ceuncorrected. The IR spectra were recorded on a Shimadzu
470 spectrometer by using potassium bromide disks. The
NMR spectra were obtained using a Bruker 400 MHz
spectrometer (Bruker Bioscience, Billerica, MA, USA).
Tetramethylsilane (TMS) was used as internal standard
and chemical shifts (δ) are reported in ppm. Mass spectra
were recorded on a Finnigan TSQ 70 spectrometer at
70 eV. Elemental analyses were carried out by using a
HERAEUS CHN-O rapid elemental analyzer (Heraeus
GmbH, Hanau, Germany) for C, H and N and the results
are within ± 0.4% of the theoretical values.
Synthesis of 3-chloro-4-hydroxy-5-methoxybenzaldehyde
(7a)
To a solution of vanillin (6a, 2.5 g, 16.4 mmol) in glacial
acetic acid (15 ml) was slowly introduced a stream of
chlorine gas over 30 min. White solid product was
filtrated, washed with n-hexane (50 ml) to give com-
pound 7a (1.9 g). The acetic acid filtrate was again
treated with chlorine gas flow as above for 30 min to
give 0.7 g of compound 7a [20]. A total of 2.6 g (85%
yield) of white solid 7a was obtained and used in next
step without purification. 1H NMR (CDCl3, 400 MHz) δ:
9.7 (s, 1H, CHO), 7.5 (d, J = 1.6 Hz, 1H, aromatic), 7.3
(d, J = 1.6 Hz, 1H, aromatic), 3.9 (s, 3H, OCH3).
Synthesis of 3-chloro-5-ethoxy-4-hydroxybenzaldehyde (7b)
3-Ethoxy-4-hydroxybenzaldehyde (6b, 4 g, 5 mmol) was
dissolved in a solution of glacial acetic acid (30 ml) and
chloroform (10 ml) at 0°C and a stream of chlorine gas
was slowly introduced over 15 min. Then, the solvents
was evaporated and the residue was purified by silica gel
column, eluting with a mixture of ethyl acetate/of chalcones exhibiting cytotoxic activity, structure of SJ-172550
ll lines and designed compounds as cytotoxic agents.
Scheme 1 General synthetic route to 3-benzylidene-4-chromanones 5a–k. Reagents and conditions: (a) 3-chloropropionic acid, CF3SO3H; (b)
2.0 M NaOH; (c) methyl iodide, K2CO3, DMF; (d) appropriate aldehyde, HCl (gas), ROH.
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yield. 1H NMR (CDCl3, 400 MHz) δ: 10.3 (s, 1H, CHO),
7.5 (br s, 1H, aromatic), 6.9 (br s, 1H, aromatic), 5.7 (s,
1H, OH), 4.2 (q, J = 7.2 Hz, 2H, CH2), 1.5 (t, J = 7.2 Hz,
3H, CH3).
Synthesis of methyl 2-(2-chloro-4-formyl-6-
methoxyphenoxy)acetate (8a)
A mixture of 5-chlorovanillin (7a, 2 g, 10.7 mmol) and
K2CO3 (1.5 g, 10.8 mmol) in ethyl methyl ketone
(40 ml) was stirred under reflux. After 10 min, methyl
bromoacetate (1.64 g, 10.8 mmol) was added, and the
mixture was allowed to stir under reflux for another 4 h.
After the reaction was completed, ethyl methyl ketone
was removed, and the residue was extracted with EtOAcScheme 2 Synthesis of aldehyde intermediates 7–9 and 11. Reagents a
CH3COCH2CH3; (c) methyl iodide, K2CO3, DMF.(3 × 10 ml). The organic layer was dried over Na2SO4
and evaporated to give compound 8a in 88.8% yield. 1H
NMR (CDCl3, 400 MHz) δ: 9.8 (s, 1H, CHO), 7.4 (d, J =
1.6 Hz, 1H, aromatic), 7.3 (d, J = 1.6 Hz, 1H, aromatic),
4.8 (s, 2H, CH2), 3.9 (s, 3H, OCH3), 3.8 (s, 3H, OCH3).
Synthesis of methyl 2-(2-chloro-6-ethoxy-4-formylphenoxy)
acetate (8b)
To a solution of compound 7b (200 mg, 1 mmol) in
ethyl methyl ketone (4 ml), was added potassium car-
bonate (147 mg, 1 mmol) and methyl bromoacetate
(153 mg, 1 mmol) successively. The mixture was stirred
under reflux for 2 h, cooled to room temperature and
the solvent was removed under reduced pressure. The
residue was added to 5 ml of water and extracted threend conditions: (a) Cl2 , CH3COOH; (b) R
2OCOCH2Br, K2CO3,
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was dried (Na2SO4), and concentrated to give 8b as a
white solid in 91% yield. 1H NMR (CDCl3, 400 MHz) δ:
10.3 (s, 1H, CHO), 7.3 (s, 1H, aromatic), 6.8 (s, 1H, aro-
matic), 4.7 (s, 2H, CH2), 4.2 (q, J = 7.2 Hz, 2H, CH2), 3.8
(s, 3H, OCH3), 1.5 (t, J = 7.2 Hz, 3H, CH3).
Synthesis of ethyl 2-(2-chloro-6-ethoxy-4-formylphenoxy)
acetate (8c)
To a solution of compound 7b (500 mg, 2.5 mmol) in
ethyl methyl ketone (10 ml), was added potassium car-
bonate (370 mg, 2.5 mmol) and ethyl bromoacetate (2.5 -
mmol) successively. The mixture was stirred under
reflux for 3 h and then the solvent was removed under
reduced pressure. The residue was added to 10 ml of
water and extracted three times with ethyl acetate
(10 ml). The combined extracts was dried (Na2SO4) and
concentrated to give 8c as a white solid in 88% yield. 1H
NMR (CDCl3, 400 MHz) δ: 10.2 (s, 1H, CHO), 7.3 (s,
1H, aromatic), 6.9 (s, 1H, aromatic), 4.7 (s, 2H, CH2),
4.25 (q, J = 7.2 Hz, 2H, CH2), 1.5 (t, J = 7.2 Hz, 3H, CH3),
1.3 (t, J = 7.2 Hz, 3H, CH3).
Synthesis of 3-chloro-4,5-dimethoxybenzaldehyde (9a)
To a solution of 5-chlorovanillin (7a, 5 g, 26.8 mmol) in
DMF (40 ml) was added potassium carbonate (3.7 g,
26.8 mmol) and iodomethane (4.56 g, 32.16 mmol) suc-
cessively. The mixture was stirred at 80°C for 3 h, cooled
to room temperature and poured to water (100 ml). The
precipitated white solid was filtrated and washed with
water to give 5.1 g of compound 9a in 94.8 yield. 1H
NMR (CDCl3, 400 MHz) δ: 9.85 (s, 1H, CHO), 7.5 (s, 1H,
aromatic), 7.35 (s, 1H, aromatic), 3.97 (s, 3H, OCH3), 3.94
(s, 3H, OCH3).
General procedure for the preparation of compounds 11a-c
A mixture of hydroxybenzaldehyde 10a-c (5 g, 40.95 mmol)
and K2CO3 (6 g, 40.95 mmol) in ethyl methyl ketone
(100 ml) was stirred under reflux. After 1 h, methyl
bromoacetate was added, and the mixture was allowed to
stir under reflux for another 3 h. After the reaction was
completed, ethyl methyl ketone was removed, and the
residue was extracted with EtOAc (3 × 20 ml). The organic
layer was dried (Na2SO4) and evaporated to give methyl
(formylphenoxy)acetate 11a-c [21].
Methyl (2-formylphenoxy)acetate (11a)
This compound was obtained using general procedure
as a pale yellow oil without further purification in 85%
yield. IR (KBr, cm-1): 1767 (C = O, ester), 1690 (C =O,
aldehyde); 1H NMR (CDCl3, 400 MHz) δ: 10.56 (s, 1H,
CHO), 7.87 (dd, J = 5.6 and 2 Hz, 1H, H6-phenyl), 7.54
(t, J = 7.6 Hz, 1H, H4-phenyl), 7.09 (t, J = 7.6 Hz, 1H, H5-phenyl), 6.86 (t, J = 8.8 Hz, 1H, H3-phenyl), 4.7 (s, 2H,
CH2), 3.8 (s, 3H, OCH3).
Methyl (3-formylphenoxy)acetate (11b)
This compound was obtained using general procedure
as a pale yellow oil without further purification in 63%
yield. IR (KBr, cm-1): 1761 (C = O, ester), 1682 (C =O,
aldehyde); 1H NMR (CDCl3, 400 MHz) δ: 10 (s, 1H,
CHO), 7.51 (m, 2H, H5, H6-phenyl), 7.36 (s, 1H, H2-
phenyl), 7.25 (br s, 1H, H4-phenyl), 4.71 (s, 2H, CH2),
3.92 (s, 3H, OCH3).
Methyl (4-formylphenoxy)acetate (11c)
This compound was obtained using general procedure
as a pale yellow oil without further purification in 93%
yield. IR (KBr, cm-1): 1742 (C = O, ester), 1695 (C =O,
aldehyde); 1H NMR (CDCl3, 400 MHz) δ: 9.9 (s, 1H,
CHO), 7.9 (d, J = 8 Hz, 2H, aromatic), 7.0 (d, J = 8 Hz,
2H, aromatic), 4.73 (s, 2H, CH2), 3.82 (s, 3H, CH3O).
Synthesis of (E)-3-(3-chloro-4-hydroxy-5-
methoxybenzylidene)-7-methoxychroman-4-one (5a)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), 5-chlorovanillin (7a, 105 mg, 0.56 mmol) in
EtOH (2 ml) was stirred at room temperature for 5 min,
while a stream of HCl gas was introduced. After 24 h at
room temperature, the precipitation was filtrated, crystal-
lized from EtOH to give 5a as red solid in 52% yield. m.p.
171–173°C; IR (KBr, cm-1): 3428 (OH), 1655 (C =O); 1H
NMR (DMSO-d6, 400 MHz) δ: 7.8 (d, J = 8.8 Hz, 1H, H5-
chromanone), 7.6 (br s, 1H, CH-vinylic), 7.07 (d, J =
1.5 Hz, 1H, H2-phenyl), 7.03 (d, J = 1.6 Hz, 1H, H6-
phenyl), 6.7 (dd, J = 6.4 and 2.4 Hz, 1H, H6-chromanone),
6.5 (d, J = 2.3 Hz, 1H, H8-chromanone), 5.4 (d, J = 1.6 Hz,
2H, H2-chromanone), 3.89 (s, 3H, OCH3), 3.83 (s, 3H,
OCH3); Anal. Calcd for C18H15ClO5: C, 62.35; H, 4.36.
Found: C, 62.04; H, 4.40.
Synthesis of (E)-3-(3-chloro-4,5-dimethoxybenzylidene)-7-
methoxychroman-4-one (5b)
A solution of 7-methoxychroman-4-one (4, 500 mg,
2.8 mmol), 3-chloro-4,5-dimethoxybenzaldehyde (9a,
562 mg, 2.8 mmol) in EtOH (10 ml) was stirred at room
temperature for 25 min, while a stream of HCl gas was in-
troduced. After 24 h at room temperature, the precipi-
tated solid was filtrated, crystallized from EtOH to afford
compound 5b as orange solid in 85% yield. m.p. 125–
127°C; IR (KBr, cm-1): 1670 (C =O); 1H NMR (CDCl3,
400 MHz) δ: 7.96 (d, J = 8.8 Hz, 1H, H5-chromanone), 7.7
(br s, 1H, CH-vinylic), 6.8 (br s, 1H, H2-phenyl), 6.7 (br s,
1H, H6-phenyl), 6.6 (d, J = 8 Hz, 1H, H6-chromanone), 6.4
(br s, 1H, H8-chromanone), 5.3 (s, 2H, H2-chromanone),
3.92 (s, 3H, OCH3), 3.9 (s, 3H, OCH3), 3.85 (s, 3H,
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Found: C, 62.88; H, 4.41.
Synthesis of (E)-methyl 2-(2-chloro-6-methoxy-4-((7-
methoxy-4-oxo-2H-chromen-3(4H)-ylidene)methyl)phenoxy)
acetate (5c)
A solution of 7-methoxychroman-4-one (4, 300 mg, 1.68
mmol), methyl 2-(2-chloro-4-formyl-6-methoxyphenoxy)
acetate (8a, 435 mg, 1.68 mmol) in MeOH (6 ml) was
stirred at room temperature for 20 min, while a stream of
HCl gas was introduced. After 24 h at room temperature,
the precipitation was filtrated, crystallized from MeOH to
give compound 5c as pink solid in 64% yield. m.p. 118–
121°C; IR (KBr, cm-1): 1767 (C =O), 1750 (C =O); 1H
NMR (CDCl3, 400 MHz) δ: 7.9 (d, J = 9.2 Hz, 1H, H5-
chromanone), 7.7 (br s, 1H, CH-vinylic), 6.9 (s, 1H, H3-
phenyl), 6.7 (s, 1H, H5-phenyl), 6.6 (d, J = 8.8 Hz, 1H,
H6-chromanone), 6.4 (br s, 1H, H8-chromanone), 5.3 (s,
2H, OCH2CO), 4.7 (s, 2H, H2-chromanone), 3.87 (s, 3H,
OCH3), 3.85 (s, 3H, OCH3), 3.83 (s, 3H, OCH3); Anal.
Calcd for C21H19ClO7: C, 60.22; H, 4.57. Found: C,
60.36; H, 4.71.
Synthesis of (E)-methyl 2-(2-chloro-6-ethoxy-4-((7-methoxy-
4-oxo-2H-chromen-3(4H)-ylidene)methyl)phenoxy)acetate
(5d)
A solution of 7-methoxychroman-4-one (4, 200 mg, 1.12 -
mmol), methyl 2-(2-chloro-6-ethoxy-4-formylphenoxy)
acetate (8b, 288 mg, 1.12 mmol) in MeOH (4 ml) was
stirred at room temperature for 25 min, while a stream of
HCl gas was introduced. After 24 h at room temperature,
the precipitated solid was filtrated, crystallized from
MeOH to give pure compound 5d as a pink solid in 52%
yield. m.p. 151–153°C; IR (KBr, cm-1): 1759 (C =O), 1737
(C =O); 1H NMR (CDCl3, 400 MHz) δ: 7.9 (d, J = 8.8 Hz,
1H, H5-chromanone), 7.8 (br s, 1H, CH-vinylic), 6.9 (s,
1H, H3-phenyl), 6.6 (br s, 2H, H6-chromanone and H5-
phenyl), 6.4 (br s, 1H, H8-chromanone), 5.1 (s, 2H, CH2),
4.7 (s, 2H, H2-chromanone), 4.1 (m, 2H, CH2), 3.85 (s, 3H,
OCH3), 3.82 (s, 3H, OCH3), 1.5 (t, J = 6.8 Hz, 3H, CH3);
Anal. Calcd for C22H21ClO7: C, 61.05; H, 4.89. Found: C,
60.83; H, 5.03.
Synthesis of (E)-ethyl 2-(2-chloro-6-ethoxy-4-((7-methoxy-4-
oxo-2H-chromen-3(4H)-ylidene)methyl)phenoxy)acetate (5e)
A solution of 7-methoxychroman-4-one (4, 50 mg, 0.28
mmol), ethyl 2-(2-chloro-6-ethoxy-4-formylphenoxy)ace-
tate (8c, 76 mg, 0.28 mmol) in EtOH (2 ml) was stirred
at room temperature for 15 min, while a stream of HCl
gas was introduced. After 24 h at room temperature, the
precipitation was filtrated, crystallized from EtOH to
give compound 5e as a white solid in 43% yield. m.p.
122–123°C; IR (KBr, cm-1): 1748 (C =O); 1H NMR
(CDCl3, 400 MHz) δ: 7.9 (d, J = 8.0, 1H, H5-chromanone),7.8 (br s, 1H, CH-vinylic), 6.9 (s, 1H, H3-phenyl), 6.6 (br s,
2H, H6-chromanone and H5-phenyl), 6.4 (s, 1H, H8-
chromanone), 5.1 (s, 2H, H2-chromanone), 4.6 (s, 2H,
OCH2CO), 4.2 (m, 2H, CH2), 4.1 (m, 2H, CH2), 3.85 (s,
3H, OCH3), 1.4 (m, 3H, CH3), 1.3 (s, 3H, CH3); Anal.
Calcd for C23H23ClO7: C, 61.82; H, 5.19. Found: C, 62.01;
H, 4.89.
Synthesis of (E)-methyl 2-(4-((7-methoxy-4-oxo-2H-chromen-
3(4H)-ylidene)methyl)phenoxy)acetate (5f)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), methyl 2-(4-formylphenoxy)acetate (11c,
109 mg, 0.56 mmol) in anhydrous MeOH (2 ml) was
stirred at room temperature for 25 min, while a stream of
HCl gas was introduced. After 24 h at room temperature,
the precipitation was filtrated, crystallized from methanol
to afford pure compound 5f as a red solid in 71% yield. m.
p. 131–133°C; IR (KBr, cm-1): 1760 (C =O), 1667 (C =O);
1H NMR (CDCl3, 400 MHz) δ: 7.8 (d, J = 8.4 Hz, 1H, H5-
chromanone), 7.6 (s, 1H, CH-vinylic), 7.41 (d, J = 8.8 Hz,
2H, H2- and H6-phenyl), 7.05 (d, J = 8.4 Hz, 2H, H3- and
H5-phenyl), 6.7 (d, J = 8.2 Hz, 1H, H6-chromanone), 6.5
(s, 1H, H8-chromanone), 5.4 (s, 2H, OCH2CO), 4.8 (s, 2H,
H2-chromanone), 3.8 (s, 3H, OCH3), 3.7 (s, 3H, OCH3);
MS, m/z: 354, 295, 281, 265, 253, 151, 131, 115, 77, 63, 45.
Anal. Calcd for C20H18O6: C, 67.79; H, 5.12; Found: C,
68.00; H, 4.98.
Synthesis of (E)-ethyl 2-(4-((7-methoxy-4-oxo-2H-chromen-3
(4H)-ylidene)methyl)phenoxy)acetate (5g)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), methyl 2-(4-formylphenoxy)acetate (11c,
109 mg, 0.56 mmol) in anhydrous EtOH (2 ml) was stirred
at room temperature for 20 min, while a stream of HCl
gas was introduced. After 24 h at room temperature, the
precipitation was filtrated, crystallized from ethanol to
give compound 5 g as a red solid in 71% yield. m.p. 133–
135°C; IR (KBr, cm-1): 1760 (C =O), 1659 (C =O); 1H
NMR (DMSO-d6, 400 MHz) δ: 7.8 (d, J = 8.4 Hz, 1H, H5-
chromanone), 7.6 (s, 1H, CH-vinylic), 7.41 (d, J = 8.8 Hz,
2H, H2- and H6-phenyl), 7.05 (d, J = 8.4 Hz, 2H, H3- and
H5-phenyl), 6.7 (d, J = 8.2 Hz, 1H, H6-chromanone), 6.5
(s, 1H, H8-chromanone), 5.4 (s, 2H, OCH2CO), 4.8 (s, 2H,
H2-chromanone), 3.8 (s, 3H, OCH3), 3.7 (s, 3H, OCH3);
MS, m/z: 368, 281, 253, 164, 151, 131, 115, 77. Anal. Calcd
for C21H20O6: C, 68.47; H, 5.47. Found: C, 68.27; H, 5.51.
Synthesis of (E)-propyl 2-(4-((7-methoxy-4-oxo-2H-chromen-
3(4H)-ylidene)methyl)phenoxy)acetate (5h)
A solution of 7-methoxychroman-4-one (4, 300 mg,
1.68 mmol), methyl 2-(4-formylphenoxy)acetate (11c,
327 mg, 1.68 mmol) in n-PrOH (6 ml) was stirred at
room temperature for 15 min, while a stream of HCl gas
was introduced. After 24 h at room temperature, the
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give compound 5 h as a pink solid in 47% yield. m.p.
102–105°C; IR (KBr, cm-1): 1758 (C =O), 1660 (C =O);
1H NMR (DMSO-d6, 400 MHz) δ: 7.8 (d, J = 8.4 Hz, 1H,
H5-chromanone), 7.6 (s, 1H, CH-vinylic), 7.4 (d, J =
8.0 Hz, 2H, H2- and H6-phenyl), 7.0 (d, J = 8.4 Hz, 2H,
H3- and H5-phenyl), 6.7 (d, J = 8.0 Hz, 1H, H6-
chromanone), 6.5 (s, 1H, H8-chromanone), 5.4 (s, 2H,
OCH2CO), 4.89 (s, 2H, H2-chromanone), 4.09 (t, J =
6.4 Hz, 2H, OCH2), 3.8 (s, 3H,OCH3), 1.6 (m, 2H, CH2),
0.87 (t, J = 7.2 Hz, 3H, CH3); MS, m/z: 382, 354, 295,
281, 265, 151, 131, 115, 77, 69, 57, 43. Anal. Calcd for
C22H22O6: C, 69.10; H, 5.80. Found: C, 68.90; H, 6.07.
Synthesis of (E)-butyl 2-(4-((7-methoxy-4-oxo-2H-chromen-3
(4H)-ylidene)methyl)phenoxy)acetate (5i)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), methyl 2-(4-formylphenoxy)acetate (11c,
109 mg, 0.56 mmol) in n-BuOH (2 ml) was stirred at
room temperature for 10 min, while a stream of HCl gas
was introduced. After 24 h at room temperature, the
precipitation was filtrated, crystallized from n-BuOH to
afford compound 5i as a pink solid in 36% yield. m.p.
85–87°C; IR (KBr, cm-1): 1766 (C =O), 1664 (C = O); 1H
NMR (DMSO-d6, 400 MHz) δ: 7.8 (d, J = 8.8 Hz, 1H,
H5-chromanone), 7.6 (br s, 1H, CH-vinylic), 7.4 (d, J =
8.0 Hz, 2H, H2- and H6-phenyl), 7.0 (d, J = 8.4 Hz, 2H,
H3- and H5-phenyl), 6.7 (d, J = 7.6 Hz, 1H, H6-
chromanone), 6.5 (br s, 1H, H8-chromanone), 5.4 (s, 2H,
OCH2CO), 4.8 (s, 2H, H2-chromanone), 4.1 (t, J =
7.6 Hz, 2H, OCH2), 3.8 (s, 3H, OCH3), 1.5 (m, 2H,
CH2), 1.3 (m, 2H, CH2), 0.8 (t, J = 7.6 Hz, 3H, CH3); MS,
m/z: 396, 281, 265, 253, 167, 149, 131, 115, 107, 81, 57,
41. Anal. Calcd for C23H24O6: C, 69.68; H, 6.10. Found:
C, 69.80; H, 6.37.
Synthesis of (E)-methyl 2-(2-((7-methoxy-4-oxo-2H-chromen-
3(4H)-ylidene)methyl)phenoxy)acetate (5j)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), methyl 2-(2-formylphenoxy)acetate (11a,
109 mg, 0.56 mmol) in anhydrous MeOH (2 ml) was
stirred at room temperature for 35 min, while a stream
of HCl gas was introduced. After 24 h at room
temperature, the precipitation was filtrated, crystallized
from methanol to give compound 5j as yellow viscous
oil in 32% yield. IR (KBr, cm-1): 1755 (C =O), 1664 (C =
O); 1H NMR (CDCl3, 400 MHz) δ: 7.98 (br s, 1H, H5-
chromanone), 7.96 (s, 1H, CH-vinylic), 7.35 (d, J =
7.6 Hz, 1H, H3-phenyl), 7.07 (m, 2H, H4- and H5-
phenyl), 6.81 (d, J = 8 Hz, 1H, H6-phenyl), 6.62 (d, J =
7.6 Hz, 1H, H6-chromanone), 6.4 (s, 1H, H8-
chromanone), 5.22 (s, 2H, OCH2CO), 4.7 (s, 2H, H2-
chromanone), 3.8 (s, 3H, OCH3), 3.79 (s, 3H, OCH3);
MS, m/z: 354, 295, 281, 265, 151, 131, 77, 67, 57, 43.Anal. Calcd for C20H18O6: C, 67.79; H, 5.12. Found: C,
68.02; H, 4.98.
Synthesis of (E)-methyl 2-(3-((7-methoxy-4-oxo-2H-chromen-
3(4H)-ylidene)methyl)phenoxy)acetate (5k)
A solution of 7-methoxychroman-4-one (4, 100 mg,
0.56 mmol), methyl 2-(3-formylphenoxy)acetate (11b,
109 mg, 0.56 mmol) in anhydrous MeOH (2 ml) was
stirred at room temperature for 30 min, while a stream
of HCl gas was introduced. After 24 h at room
temperature, the precipitation was filtrated, crystallized
from methanol to give compound 5 k as a pink solid in
79% yield. m.p. 111–114°C; IR (KBr, cm-1): 1758 (C = O),
1670 (C =O); 1H NMR (DMSO-d6, 400 MHz) δ: 7.8 (d,
J = 8.8 Hz, 1H, H5-chromanone), 7.7 (s, 1H, CH-vinylic),
7.4 (t, J = 6.8 Hz, 1H, H6-phenyl), 7.0 (m, 3H, H2 and
H4- and H5-phenyl), 6.7 (dd, J = 6.8 and 2.0 Hz, 1H, H6-
chromanone), 6.5 (d, J = 2.0 Hz, 1H, H8-chromanone),
5.4 (s, 2H, OCH2CO), 4.9 (s, 2H, H2-chromanone), 3.8
(s, 3H, OCH3), 3.7 (s, 3H, OCH3); MS, m/z: 354, 281,
178, 167, 150, 122, 107, 79, 69, 57, 43. Anal. Calcd for
C20H18O6: C, 67.79; H, 5.12. Found: C, 67.65; H, 5.33.
Cytotoxicity assay
The in-vitro cytotoxic activity of each synthesized com-
pounds 5a-k was assessed using MTT colorimetric assay
according to the literature method [22]. Each set of ex-
periments was independently performed three times. For
each compound, the concentration causing 50% cell
growth inhibition (IC50) compared with the control was




Reaction sequence employed for the synthesis of (E)-3-
benzylidene-7-methoxychroman-4-one derivatives 5a-k
is shown in Scheme 1. The reaction of resorcinol 1
with 3-chloropropionic acid in the presence of tri-
fluoromethane sulfonic acid furnished 2′,4′-dihydroxy-
3-chloropropiophenone (2) which was cyclized using
2 M NaOH to give 7-hydroxy-4-chromanone (3). Com-
pound 4 was obtained by reacting intermediate 3 with
iodomethane in the presence of potassium carbonate in
DMF. Condensation of 7-methoxychroman-4-one (4)
with suitable aldehydes 7–9 and 11 in appropriate alco-
hol in the presence of gaseous HCl gave the target com-
pounds 5a-k.
The corresponding aldehydes 7–9 and 11 were pre-
pared as shown in Scheme 2. Chlorination of 3-alkoxy-
4-hydroxybenzaldehyde 6a,b using acetic acid as a solv-
ent gave 3-chloro-4-hydroxy-5-alkoxybenzaldehyde 7a,b
which was reacted with suitable alkyl bromoacetate, in
the presence of potassium carbonate to give compounds
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10.53 ± 0.86 >100 >100
Etoposide 21.2 ± 2.12 18.93 ± 1.78 14.04 ± 1.05
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7a afforded dimethoxybenzaldehyde derivative 9a. Me-
thyl (formylphenoxy)acetate 11a-c was synthesized by
heating compounds 10a-c with methyl bromoacetate
and potassium carbonate in ethyl methyl ketone.
In vitro cytotoxic activity
The cytotoxic activity of synthesized compounds 5a-k
was evaluated against three cell lines namely MDA-MB-
231 (breast cancer), KB (nasopharyngeal epidermoid
carcinoma) and SK-N-MC (human neuroblastoma) cells.
The results of cytotoxic assay were mentioned as IC50
(μg/ml) of compounds in comparison with reference
drug etoposide in Table 1.
In the case of MDA-MB-231 cell line, the IC50 values
of all compounds were ≤20 μg/ml with the exception of
compounds 5d and 5e. Furthermore, compounds 5b
and 5i exhibited the highest cytotoxic activity against
this cell line (IC50 < 10 μg/ml). Compound 5b was also
the most potent derivative against KB cell line with IC50
value of 25.04 μg/ml. Beside compound 5b, compound
5a exhibited good activity against KB cells, but
remaining compounds 5c-k showed no activity against
this cell line (IC50 >100 μg/ml). Against SK-N-MC cells,
compound 5b followed by compounds 5a and 5c
showed significant inhibitory activity with IC50 values of
9.64, 12.6 and 58.04 μg/ml, respectively.
Overall, it is clear that among the test compounds
described in this study, the 3-chloro-4,5-dimethoxy-
benzylidene derivative 5b demonstrated better cytotoxic
profile against all tested cell lines (IC50 values = 7.56–
25.04 μg/ml). Generally, the comparison of IC50 values
of compound 5b with those of etoposide demonstrated
that the cytotoxic activity of compound 5b against MDA-
MB-231 and SK-N-MC cells is more than etoposide.
In this work, as part of an ongoing program to find
new cytotoxic agents, we have focused our attention on
modification of the 3-benzylidene-4-chromanones and
introducing new functionality on the benzylidene moiety.Thus, we designed novel 3-benzylidene-4-chromanones
that possessed a 2-(2-chloro-6-alkoxyphenoxy)acetic acid
ester. These modifications were made on the basis of SJ-
172550, a new cytotoxic agent possessing 2-(2-chloro-6-
ethoxyphenoxy)acetic acid methyl ester attached to the
pyrazolone ring. Surprisingly, compound 5d, the chro-
manone analog of SJ-172550 showed no activity against
tested cell lines. Also, the ethyl ester counterpart of 5d
(compound 5e) was inactive against tumor cell lines.
However, the 2-(2-chloro-6-methoxyphenoxy)acetic acid
methyl ester analog 5c was active against MDA-MB-231
and SK-N-MC cells. We have briefly investigated the SAR
of compounds by simplification of the functionality on the
benzylidene part of the basic molecule.
As can be deduced from the cytotoxic data of
compounds 5f-k which characterized by the lack of 2-
chloro-6-alkoxy functionality, the cytotoxic activity against
MDA-MB-231 can be served by the simple phenoxyacetic
acid ester derivatives. However, the lack of 2-chloro-6-alk-
oxy functionality results in the lack of activity against KB
and SK-N-MC cells. Among the compounds 5f-k, butyl
ester derivative 5i showed the highest activity against
MDA-MB-231 being 3-fold more potent than standard
drug etoposide.
To determine the effect of acetic acid ester substitu-
tion in compound 5c, we prepared both the 4-hydroxy
derivative 5a and 4-methoxy analog 5b. When compared
to 5c, both compounds had similar or better in vitro ac-
tivities against tested cell lines.
The cytotoxic activities of regio-isomeric compounds
5f, 5j and 5 k against MDA-MB-231cells revealed that
changing the position of oxyesteric group has led to
non-significant changes in activities. As seen from data,
in poly-substituted compounds changing of methoxy
group on phenyl ring to ethoxy group (for example 5d
versus 5c) dramatically decreased the cytotoxic potency
in MDA-MB-231 and SK-N-MC cells.
In summary, in the pursuit for finding new cytotoxic
agents, we replaced the pyrazolone part of well-known
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one. Although the direct analog of SJ-172550 (com-
pound 5d) did not show any cytotoxic activity against
tested cell lines, but 2-(2-chloro-6-methoxyphenoxy)
acetic acid methyl ester analog 5c showed some activity
against MDA-MB-231 and SK-N-MC cells. Further modi-
fication of compound 5c resulted in the 3-chloro-4,5-
dimethoxybenzylidene derivative 5b which demonstrated
better cytotoxic profile against all tested cell lines (IC50
values = 7.56–25.04 μg/ml).
It is worthwhile to mention that, since we have origin-
ally designed the target compounds based on p53-
dependent cytotoxic agent SJ-172550, it was better using
the latter compound as standard drug in our cytotoxic
assay. However, our primary cytotoxic experiments on
the closest compound to SJ-172550 (compound 5d) in a
side-by-side comparison manner with etoposide revealed
that compound 5d had no activity against cancer cell lines.
On the other hand, simplified compounds 5a and 5b with
more dissimilarity respect to the SJ-172550 showed better
profile of cytotoxicity. Based on these results, it seems that
a different mechanism is responsible for potential cyto-
toxic activity of compound 5b prototype.
We employed MTT cell viability assay as a standard
and well-documented in vitro method for evaluation of
the cytotoxic potential of designed compounds. Al-
though these types of in vitro models are beneficial and
promising as early screening tools for finding new lead
compounds, but these models are associated with some
limitations [23]. Thus, for efficacy and safety evaluation
of lead compounds, conducting a method based on ani-
mal model is necessary in the next steps of study.
In conclusion, the results demonstrated that the cyto-
toxic activity of 3-(3-chloro-4,5-dimethoxybenzylidene)-
7-methoxychroman-4-one (5b) against MDA-MB-231
and SK-N-MC cells is more than standard drug etoposide.
Therefore, compound 5b prototype bearing 3-chloro-4,5-
dimethoxybenzylidene moiety could be considered as
novel lead compound for further developing new antican-
cer chemotherapeutics. Although, compound 5b showed
promising activity in vitro, but to identify a promising an-
ticancer drug candidate that has good pharmacokinetic
and toxicological profiles, the in vivo ADME-Tox studies
of compound 5b prototype should be conducted.
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